BioSpace News Archive

Despite having achieved a record net sales of $477 million driven by the success of its powerhouse medication Adcetris in 2018, as well as a 58 percent increase in sales during the fourth quarter in comparison to the previous year, Seattle Genetics stock fell as the results did not meet analysts’ expectations.

Kodiak Sciences Inc. announced that a presentation on its investigational therapy KSI-301 will be made at the Angiogenesis, Exudation, and Degeneration 2019 meeting being held on February 9, 2019 in Miami, FL.

Executive Management to Host Conference Call on February 21, 2019 at 4:30 p.m. ET

OncoSec Medical Incorporated announced that Dan O’Connor, President, Director & Chief Executive Officer, will present a company overview at the BIO CEO & Investor Conference on Monday, February 11, 2019, at 9:00 a.m. ET in New York, NY.

Mini “bear hug” and “lots of love” benefit lifesaving mission of St. Jude

Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today released the final voting results from the Annual Shareholder Meeting held on February 2, 2019.

Neurotrope Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), today announced that Charles Ryan, J.D., Ph.D., Neurotrope’s Chief Executive Officer, will be participating in an educational panel entitled, “Attacking Biological Mechanisms of Aging to Extend Healthspan” at the BIO CEO & Investor Conference

The Michigan Mesothelioma Victims Center says, “We are the top ranked source in the nation for the ‘best mesothelioma or asbestos exposure lung cancer compensation for a diagnosed person in Michigan’ especially if the person’s exposure to asbestos occurred at an auto or truck manufacturing facility.

According to Coherent Market Insights, the global bioresorbable implants market was valued at US$ 5,543.1 million in 2017, and is projected to exhibit a CAGR of 7.7% over the forecast period (2018 – 2026).

Joining the healthcare business intelligence sector is a new sophisticated market intelligence tool that provides unparalleled insight into hospital clinical performance and costs.